Shearman & Sterling advised HalioDx, a diagnostic company expert in immuno-oncology, on the closing of an €18.5 million Series B financing after a Series A round of €8 million in March 2015.

The latest round was led by Bpifrance’s PSIM fund, which was joined by Capricorn Venture Partners and Amundi Private Equity Funds. The fundraising will accelerate the development of HalioDx’s Immunoscore platform for colon cancer and other types of cancer and allow the company to set up commercial activities in the U.S.